Published in Lancet on October 25, 1975
A perspective of polyamine metabolism. Biochem J (2003) 3.24
Polyamine levels in normal human skin. A comparative study of pure epidermis, pure dermis, and suction blister fluid. Arch Dermatol Res (1983) 0.88
Plasma spermidine concentrations as early indication of response to therapy in human myeloma. J Clin Pathol (1983) 0.78
Altered polyamine metabolism in the PRO/Re strain of inbred mice. Biochem J (1976) 0.75
Predicting response to chemotherapy for patients with epithelial ovarian cancer using urinary polyamine excretion patterns. Br J Cancer (1990) 0.75
Polyamines in colorectal cancer--a clinical and experimental approach. J Clin Pathol (1983) 0.75
Studies with cis-diamminedichloro-platinum II and exogenous polyamines using mammalian cells in culture. Br J Cancer (1981) 0.75
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer (1975) 10.04
Primary bioassay of human tumor stem cells. Science (1977) 9.69
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78
High speed scintillation autoradiography. Science (1975) 5.15
Raised serum levels of tumour necrosis factor in parasitic infections. Lancet (1986) 3.23
Amine synthesis in regenerating rat liver: extremely rapid turnover of ornithine decarboxylase. Mol Pharmacol (1969) 3.21
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Primary bioassay of human myeloma stem cells. J Clin Invest (1977) 2.25
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Direct cloning of human ovarian carcinoma cells in agar. Cancer Res (1978) 2.24
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest (1970) 2.21
B-cell neoplasia in man. Lancet (1974) 2.11
Tandem quadrupole Fourier-transform mass spectrometry of oligopeptides and small proteins. Proc Natl Acad Sci U S A (1987) 1.96
Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med (1979) 1.94
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92
Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med (1987) 1.82
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res (1986) 1.75
"Sandwich" solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol (1969) 1.74
Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med (1990) 1.72
Coupling high-pressure MALDI with ion mobility/orthogonal time-of-flight mass spectrometry. Anal Chem (2000) 1.69
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol (1991) 1.64
Determination of the protein composition of the occlusion-derived virus of Autographa californica nucleopolyhedrovirus. Proc Natl Acad Sci U S A (2003) 1.62
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol (1996) 1.57
Proteolysis in mixed organic-aqueous solvent systems: applications for peptide mass mapping using mass spectrometry. Anal Chem (2001) 1.53
Effect of host-cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer (1980) 1.52
Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res (1977) 1.52
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells. Cancer Res (1979) 1.51
Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood (1990) 1.50
Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol (1985) 1.47
The dynamics of synthesis and degradation of polyamines in normal and regenerating rat liver and brain. J Biol Chem (1970) 1.47
Identification of the naturally occurring flavin of nitroalkane oxidase from fusarium oxysporum as a 5-nitrobutyl-FAD and conversion of the enzyme to the active FAD-containing form. J Biol Chem (1997) 1.42
Myeloperoxidase deficiency. Immunologic study of a genetic leukocyte defect. N Engl J Med (1970) 1.41
Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood (1991) 1.40
Immunology of the lower respiratory tract. II. The plaque-forming response of canine lymphoid tissues to sheep erythrocytes after intrapulmonary or intravenous immunization. J Clin Invest (1974) 1.39
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer (1975) 1.39
Kinetics of tumor growth and regression in IgG multiple myeloma. J Clin Invest (1972) 1.38
Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology (1980) 1.37
Prolactin receptors on human lymphocytes and their modulation by cyclosporine. Biochem Biophys Res Commun (1984) 1.33
Increased polyamine concentrations in the urine of human cancer patients. Nat New Biol (1971) 1.32
Purification and characterization of S-adenosyl-L-methionine decarboxylase from rat liver. Biochemistry (1972) 1.32
The roles of the polyamines, putrescine, spermidine, and spermine in normal and malignant tissues. Life Sci (1973) 1.30
Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep (1984) 1.30
Immunoglobulin synthesis and tumour cell number and the natural history of multiple myeloma. Br Med J (1971) 1.30
Cyclic AMP, cyclic AMP-dependent protein kinase, and the regulation of gene expression. Life Sci (1977) 1.29
Posttranslational modification of ornithine decarboxylase by its product putrescine. Biochem Biophys Res Commun (1981) 1.29
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol (1983) 1.28
Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med (1982) 1.27
Polyamine biosynthesis and accumulation during the G1 to S phase transition. J Cell Physiol (1977) 1.26
Application of a human tumor colony-forming assay to new drug screening. Cancer Res (1985) 1.26
Amine synthesis in regenerating rat liver: effect of hypophysectomy and growth hormone on ornithine decarboxylase. Endocrinology (1969) 1.25
Skin reactivity in patients with cancer. Impaired delayed hypersensitivity or faulty inflammatory response? N Engl J Med (1971) 1.24
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst (1992) 1.23
Proposed model of major sequential biochemical events of a trophic response. Life Sci (1976) 1.22
Staging and kinetics of multiple myeloma. Semin Oncol (1986) 1.19
Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood (1980) 1.18
Clinical relevance of polyamines as biochemical markers of tumor kinetics. Clin Chem (1977) 1.18
On the structure elucidation using ion mobility spectrometry and molecular dynamics. J Phys Chem A (2009) 1.18
Growth hormone induction of ornithine decarboxylase in rat liver. Endocrinology (1970) 1.17
Cell cycle-specific activity of type I and type II cyclic adenosine 3':5'-monophosphate-dependent protein kinases in Chinese hamster ovary cells. J Biol Chem (1976) 1.17
Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol (1973) 1.17
Ornithine decarboxylase as a biological and pharmacological tool. Pharmacology (1980) 1.16
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood (1993) 1.16
Urinary polyamines in cancer patients. Cancer Res (1971) 1.15
Immunology of the lower respiratory tract. Functional properties of bronchoalveolar lymphocytes obtained from the normal canine lung. J Clin Invest (1973) 1.15
Inhibition of human melanoma colony formation by retinoids. Cancer Res (1979) 1.13
Concanavalin A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity and immunoreactivity. Biochem Biophys Res Commun (1987) 1.13
Lymphocyte stimulation: selective destruction of cells during blastogenic response to transplantation antigens. Science (1971) 1.13
Hydrolysis and protein binding of melphalan. J Pharm Sci (1978) 1.10
Ornithine decarboxylase activity: control by cyclic nucleotides. Science (1975) 1.09
Peptide-encoding for structure determination of nonsequenceable polymers within libraries synthesized and tested on solid-phase supports. Pept Res (1993) 1.07
Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol (1986) 1.07
Experimental and theoretical studies of (CsI)n Cs+ cluster ions produced by 355 nm laser desorption ionization. J Phys Chem A (2008) 1.07
Type I and type II cyclic AMP-dependent protein kinase as opposite effectors of lymphocyte mitogenesis. Nature (1977) 1.07
Measurement of putrescine, spermidine, and spermine in physiological fluids by use of an amino acid analyzer. Clin Chem (1973) 1.07
Isolation and characterization of two distinct forms of liver fatty acid binding protein from the rat. Biochim Biophys Acta (1999) 1.06
Differential expression of type I and type II cyclic AMP-dependent protein kinases during cell cycle and cyclic AMP-induced growth arrest. Proc Natl Acad Sci U S A (1980) 1.05
Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet (1995) 1.05
Indium-111 bleomycin tumor scanning in lymphoma. Med Pediatr Oncol (1975) 1.04
Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol (1981) 1.04
Clinical relevance of polyamines. Crit Rev Clin Lab Sci (1983) 1.04
Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci U S A (1990) 1.04
Reappraisal of plateau phase in myeloma. Lancet (1980) 1.04
Polyamine synthesis in rapidly growing tissues. Fed Proc (1970) 1.04